Diagnostic BioSystems

Diagnostic BioSystems Diagnostic Biosystems is leading developer of high quality immunohistochemistry reagents, producing

05/27/2026

Eid Mubarak!

Brain Cancer Awareness: Advancing Diagnostics and Early Detection Brain cancer is a serious health condition that re...
05/27/2026

Brain Cancer Awareness: Advancing Diagnostics and Early Detection


Brain cancer is a serious health condition that requires accurate diagnosis and timely treatment. Although it is less common than many other cancers, brain and central nervous system (CNS) tumors can be complex and life-threatening.

Immunohistochemistry (IHC) plays an important role in identifying different types of brain cancers by detecting specific tumor markers, helping pathologists determine tumor origin and support effective treatment decisions.

Read More: https://dbiosys.com/brain-cancer-awareness-month-2026

Annual Sales Budget Meet 2026-27 An inspiring journey of vision, strategy, and teamwork marked the beginning of ou...
05/15/2026

Annual Sales Budget Meet 2026-27


An inspiring journey of vision, strategy, and teamwork marked the beginning of our Annual Sales Budget Meet 2026–27.

Together, we set ambitious goals, strengthened collaboration, and paved the way for greater success ahead.

Team Spirit Day

A wonderful day filled with energy, laughter, and team spirit. Strong teams are built not only in meetings, but also through moments of fun and togetherness.

Collaborative Learning Session

Focused on learning, innovation, and hands-on troubleshooting to strengthen our technical expertise.

Continuous learning drives confidence, quality, and future success.
Website: https://dbiosys.com

05/08/2026

See Beyond the Surface – Precision in Every Stain


Melanoma is one of the most aggressive forms of Skin Cancer and is responsible for the majority of skin cancer-related deaths. Early and accurate diagnosis remains essential for improving patient outcomes.

Histopathology combined with Immunohistochemistry (IHC) plays a crucial role in distinguishing benign from malignant melanocytic lesions, guiding timely and confident clinical decisions.

Read More: https://dbiosys.com/melanoma-skin-cancer-awareness-month/

04/29/2026

Catch it early, catch it right — with Diagnostic BioSystems IHC solutions, we support accurate Head & Neck Cancer diagnosis for better treatment. 🎗️


Head and neck cancer may not always get the attention it deserves, but awareness is one of the strongest tools in fighting it. These cancers can develop in areas such as the mouth, throat, voice box, nasal cavity, salivary glands, and sinuses. Detecting it early can greatly improve treatment outcomes and quality of life.

The Power of Prevention

Early detection is your superpower! Regular health check-ups, recognizing warning signs, and reducing lifestyle risk factors can make a major difference. Common risk factors include to***co use, alcohol consumption, HPV infection.

When it comes to diagnosis, Immunohistochemistry (IHC) plays a critical role in identifying tumor origin, classification, and prognosis.

Read More: https://dbiosys.com/head-and-neck-cancer-awareness/

04/16/2026

Catch it early, catch it right, with immunohistochemistry (IHC), we bring Bowel cancer for the better treatments. IHC detection is a key to the fight!



Colorectal cancer (CRC) is a primary epithelial malignancy that arises in the colore**um. More than 1 million new cases occur worldwide per year. It is the second or third most common cancer and cause of cancer deaths in men and in women. Approximately 98% of colonic cancers are adenocarcinomas. CRC represents most common gastrointestinal tumor in U.S.; less common in Africa, Asia and parts of South America. Peak age for CRC to occur is 60 - 79 years, < 20% of cases occur before age 50 and rare before age 40, except in patients with a predisposition syndrome. CRC may arise anywhere in the colore**um but sigmoid colon and re**um are most common sites. Around 60% of patients have lymph node or distant metastases at diagnosis and most common metastatic sites are regional lymph nodes, liver, peritoneum, lung, ovaries. Five year survival is 40% - 60% and most recurrences are within 2 years.

CK20 &CK7: The most common immunophenotype of colorectal cancer is positivity for CK20 and negativity for CK7, which is a relatively specific staining pattern for colorectal primary origin of the colore**um. However, maybe up to 20% of the tumors may exhibit a CK7-positve/CK20-negative staining pattern. It has been suggested that reduced or absent CK20 expression in colorectal cancer is associated with MSI-H.

CDX2 is a marker of enteric differentiation and a highly sensitive marker for adenocarcinomas of colorectal origin. Positive in >90% of colorectal cancers. However, CDX2 can be positive in any carcinoma that shows enteric differentiation, and thus is not entirely colorectal-specific.

SATB2 is a highly specific marker for distinguishing lower gastrointestinal differentiation.

MSI (Microsatellite Instability): DNA Mismatch repair (MMR) protein antibodies, MLH1, MSH2, MSH6, PMS2, are used to detect deficient MMR status. Loss of expression in these proteins acts as a surrogate marker for Microsatellite Instability High (MSI-H), which is crucial for immunotherapy decisions.

Approximately 15% colorectal cancer show dMMR, and 80% of dMMR colorectal cancer is sporadic, 20% of dMMR colorectal cancer is familiar such as Lynch syndrome. dMMR colorectal cancer has predilection for the right colon.

04/16/2026

Let’s Talk About Oral Cancer: Prevention Starts with Awareness!


Oral cancer might not be the first thing you think about when it comes to health, but it’s important to keep an eye on your mouth! It can develop in places like your lips, gums, tongue, and throat – and catching it early is key to better outcomes.

The Power of Prevention Early detection is your superpower! Regular check-ups, self-exams, and keeping those oral habits in check can help catch things before they go rogue. Greater than 90% of cancers in the oral cavity are squamous cell carcinoma.

Read More: https://dbiosys.com/oral-cancer-awareness-2026/

04/03/2026

Testicular Cancer Awareness Month! 🎗️


We are committed to support early detection through precise cancer marker identification. Our reagents help pathologists diagnose and research testicular cancer, ensuring better patient outcomes.

Shedding light on the key markers:

OCT3/4: A marker that can identify almost all seminoma and embryonal carcinoma, however, is negative in Yolk sac tumor, teratoma, sertoli-leydig cell tumor and lymhomas. It helps pathologist in making definite diagnose and staging testicular cancer.

SALL4: Highly expressed in nearly all non-trophoblastic germ cell tumors, such as seminoma, embryonal carcinoma, yolk sac tumor, and germ cell neoplasia in situ. It should be recognized that this marker is also expressed in malignant rhabdoid tumor, Wilms tumor, acute myeloid leukemia, diffuse large B cell lymphoma and hepatocellular carcinoma.

PLAP (Placental Alkaline Phosphatase): A marker found in seminomas (100%) with strong diffuse membranous and cytoplasmic staining positivity, very useful in distinquishing seminoma from spermatocytic tumor. However, it is frequently in low intensity focally expressed in embryonal carcinoma and yolk sac tumor. It helps pathologists confirm tumor types and monitor treatment progress.

Read More: https://dbiosys.com/testicular-cancer-awareness-2026/

03/28/2026

Multiple Myeloma Awareness Month!


Did you know? Your plasma cells, which are usually the heroes of your immune system, can sometimes go rogue and turn into villains!

Bone marrow based, multifocal plasma cell neoplasm usually associated with a monoclonal immunoglobulin (M protein) in serum or urine and evidence of organ damage related to the plasma cell neoplasm. Approximately 1.8% of malignant tumor diagnoses are made in the U.S. annually with M:F = 1.2:1. The disease occurs twice as frequently in African Americans compared to Caucasians. It is usually not seen in children, rarely seen in adults under the age of 30; median age of diagnosis being ~70 years. Almost all cases appear to arise in patients with precursor monoclonal gammopathy of undetermined significance (MGUS). When pathologists make a diagnosis of multiple myeloma, they usually need to combine history, clinical manifestations, plasma cell morphology, radiation images and accessory tools such flow cytometry and immunohistochemistry (IHC) as well.

Almost all cases of bone marrow biopsies and cytology aspiration dry slides would need IHC examination for an accurate diagnosis and classification. The IHC would show positivity of plasma cell neoplastic cells, such as positive in CD138, MUM1, EMA, CD79a (almost 100%), CD56 (75 - 80%), CD200 (60 - 75%), CD28 (~40%), CD117 / KIT (20 - 35%), CD20 (10 - 20%), CD52 (8 - 14%), CD10 and occasional myeloid or monocytic markers. The neoplastic plasma cells are also monoclonal light chain dominance, with either kappa or lambda chain. Cyclin D1 positive in presence of t(11;14)(q13;q32), variable expression levels with hyperdiploidy or 11q13 amplification. t(11;14) translocation associated with expression of B cell markers on the clonal plasma cells including CD19, CD20, CD79a . Increased MYC expression may be seen and potentially distinguish multiple myeloma from MGUS. Nearly always CD19 and CD45 negative in contrast to normal plasma cells (except with t(11;14) translocation).

Website: https://dbiosys.com/products/

Warm Wishes on Sri Rama Navami! 🙏 🕉️ 🌼 🌸 ✨
03/27/2026

Warm Wishes on Sri Rama Navami! 🙏 🕉️ 🌼 🌸 ✨

03/19/2026

Happy Eid Ul-Fitr 🕌🌙✨

Address

6616 Owens Drive
Pleasanton, CA
94588

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+19254843350

Website

Alerts

Be the first to know and let us send you an email when Diagnostic BioSystems posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Diagnostic BioSystems:

Shortcuts

Featured

Share

Category